The global market for T Cell Antigen Gp39 was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for T Cell Antigen Gp39 is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for T Cell Antigen Gp39 is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, ImmuNext, Inc., Juno Therapeutics Inc., MedImmune, LLC, Targovax AS, XL-protein GmbH, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for T Cell Antigen Gp39, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding T Cell Antigen Gp39.

The T Cell Antigen Gp39 market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global T Cell Antigen Gp39 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the T Cell Antigen Gp39 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of T Cell Antigen Gp39 Market Report

Report Metric	Details
Report Name	T Cell Antigen Gp39 Market
Segment by Type	ECI-006 Hepatitis B Vaccine INX-021 ISF-35 Others
Segment by Application	Graft Versus Host Disease Breast Cancer Bladder Cancer Panceratic Cancer Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, ImmuNext, Inc., Juno Therapeutics Inc., MedImmune, LLC, Targovax AS, XL-protein GmbH
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of T Cell Antigen Gp39 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the T Cell Antigen Gp39 Market report?

Ans: The main players in the T Cell Antigen Gp39 Market are Biogen, Inc., Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, ImmuNext, Inc., Juno Therapeutics Inc., MedImmune, LLC, Targovax AS, XL-protein GmbH

What are the Application segmentation covered in the T Cell Antigen Gp39 Market report?

Ans: The Applications covered in the T Cell Antigen Gp39 Market report are Graft Versus Host Disease, Breast Cancer, Bladder Cancer, Panceratic Cancer, Others

What are the Type segmentation covered in the T Cell Antigen Gp39 Market report?

Ans: The Types covered in the T Cell Antigen Gp39 Market report are ECI-006, Hepatitis B Vaccine, INX-021, ISF-35, Others

1 T Cell Antigen Gp39 Market Overview

1.1 Product Definition

1.2 T Cell Antigen Gp39 by Type

1.2.1 Global T Cell Antigen Gp39 Market Value Comparison by Type (2024 VS 2031)

1.2.2 ECI-006

1.2.3 Hepatitis B Vaccine

1.2.4 INX-021

1.2.5 ISF-35

1.2.6 Others

1.3 T Cell Antigen Gp39 by Application

1.3.1 Global T Cell Antigen Gp39 Market Value by Application (2024 VS 2031)

1.3.2 Graft Versus Host Disease

1.3.3 Breast Cancer

1.3.4 Bladder Cancer

1.3.5 Panceratic Cancer

1.3.6 Others

1.4 Global T Cell Antigen Gp39 Market Size Estimates and Forecasts

1.4.1 Global T Cell Antigen Gp39 Revenue 2020-2031

1.4.2 Global T Cell Antigen Gp39 Sales 2020-2031

1.4.3 Global T Cell Antigen Gp39 Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 T Cell Antigen Gp39 Market Competition by Manufacturers

2.1 Global T Cell Antigen Gp39 Sales Market Share by Manufacturers (2020-2025)

2.2 Global T Cell Antigen Gp39 Revenue Market Share by Manufacturers (2020-2025)

2.3 Global T Cell Antigen Gp39 Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of T Cell Antigen Gp39, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of T Cell Antigen Gp39, Product Type & Application

2.7 Global Key Manufacturers of T Cell Antigen Gp39, Date of Enter into This Industry

2.8 Global T Cell Antigen Gp39 Market Competitive Situation and Trends

2.8.1 Global T Cell Antigen Gp39 Market Concentration Rate

2.8.2 The Global 5 and 10 Largest T Cell Antigen Gp39 Players Market Share by Revenue

2.8.3 Global T Cell Antigen Gp39 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global T Cell Antigen Gp39 Market Scenario by Region

3.1 Global T Cell Antigen Gp39 Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global T Cell Antigen Gp39 Sales by Region: 2020-2031

3.2.1 Global T Cell Antigen Gp39 Sales by Region: 2020-2025

3.2.2 Global T Cell Antigen Gp39 Sales by Region: 2026-2031

3.3 Global T Cell Antigen Gp39 Revenue by Region: 2020-2031

3.3.1 Global T Cell Antigen Gp39 Revenue by Region: 2020-2025

3.3.2 Global T Cell Antigen Gp39 Revenue by Region: 2026-2031

3.4 North America T Cell Antigen Gp39 Market Facts & Figures by Country

3.4.1 North America T Cell Antigen Gp39 Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America T Cell Antigen Gp39 Sales by Country (2020-2031)

3.4.3 North America T Cell Antigen Gp39 Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe T Cell Antigen Gp39 Market Facts & Figures by Country

3.5.1 Europe T Cell Antigen Gp39 Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe T Cell Antigen Gp39 Sales by Country (2020-2031)

3.5.3 Europe T Cell Antigen Gp39 Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific T Cell Antigen Gp39 Market Facts & Figures by Region

3.6.1 Asia Pacific T Cell Antigen Gp39 Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific T Cell Antigen Gp39 Sales by Region (2020-2031)

3.6.3 Asia Pacific T Cell Antigen Gp39 Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America T Cell Antigen Gp39 Market Facts & Figures by Country

3.7.1 Latin America T Cell Antigen Gp39 Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America T Cell Antigen Gp39 Sales by Country (2020-2031)

3.7.3 Latin America T Cell Antigen Gp39 Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa T Cell Antigen Gp39 Market Facts & Figures by Country

3.8.1 Middle East and Africa T Cell Antigen Gp39 Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa T Cell Antigen Gp39 Sales by Country (2020-2031)

3.8.3 Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global T Cell Antigen Gp39 Sales by Type (2020-2031)

4.1.1 Global T Cell Antigen Gp39 Sales by Type (2020-2025)

4.1.2 Global T Cell Antigen Gp39 Sales by Type (2026-2031)

4.1.3 Global T Cell Antigen Gp39 Sales Market Share by Type (2020-2031)

4.2 Global T Cell Antigen Gp39 Revenue by Type (2020-2031)

4.2.1 Global T Cell Antigen Gp39 Revenue by Type (2020-2025)

4.2.2 Global T Cell Antigen Gp39 Revenue by Type (2026-2031)

4.2.3 Global T Cell Antigen Gp39 Revenue Market Share by Type (2020-2031)

4.3 Global T Cell Antigen Gp39 Price by Type (2020-2031)

5 Segment by Application

5.1 Global T Cell Antigen Gp39 Sales by Application (2020-2031)

5.1.1 Global T Cell Antigen Gp39 Sales by Application (2020-2025)

5.1.2 Global T Cell Antigen Gp39 Sales by Application (2026-2031)

5.1.3 Global T Cell Antigen Gp39 Sales Market Share by Application (2020-2031)

5.2 Global T Cell Antigen Gp39 Revenue by Application (2020-2031)

5.2.1 Global T Cell Antigen Gp39 Revenue by Application (2020-2025)

5.2.2 Global T Cell Antigen Gp39 Revenue by Application (2026-2031)

5.2.3 Global T Cell Antigen Gp39 Revenue Market Share by Application (2020-2031)

5.3 Global T Cell Antigen Gp39 Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Biogen, Inc.

6.1.1 Biogen, Inc. Company Information

6.1.2 Biogen, Inc. Description and Business Overview

6.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio

6.1.5 Biogen, Inc. Recent Developments/Updates

6.2 Bristol-Myers Squibb Company

6.2.1 Bristol-Myers Squibb Company Company Information

6.2.2 Bristol-Myers Squibb Company Description and Business Overview

6.2.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio

6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.3 eTheRNA Immunotherapies NV

6.3.1 eTheRNA Immunotherapies NV Company Information

6.3.2 eTheRNA Immunotherapies NV Description and Business Overview

6.3.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.3.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio

6.3.5 eTheRNA Immunotherapies NV Recent Developments/Updates

6.4 ImmuNext, Inc.

6.4.1 ImmuNext, Inc. Company Information

6.4.2 ImmuNext, Inc. Description and Business Overview

6.4.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.4.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio

6.4.5 ImmuNext, Inc. Recent Developments/Updates

6.5 Juno Therapeutics Inc.

6.5.1 Juno Therapeutics Inc. Company Information

6.5.2 Juno Therapeutics Inc. Description and Business Overview

6.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio

6.5.5 Juno Therapeutics Inc. Recent Developments/Updates

6.6 MedImmune, LLC

6.6.1 MedImmune, LLC Company Information

6.6.2 MedImmune, LLC Description and Business Overview

6.6.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.6.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio

6.6.5 MedImmune, LLC Recent Developments/Updates

6.7 Targovax AS

6.7.1 Targovax AS Company Information

6.7.2 Targovax AS Description and Business Overview

6.7.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Targovax AS T Cell Antigen Gp39 Product Portfolio

6.7.5 Targovax AS Recent Developments/Updates

6.8 XL-protein GmbH

6.8.1 XL-protein GmbH Company Information

6.8.2 XL-protein GmbH Description and Business Overview

6.8.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2020-2025)

6.8.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio

6.8.5 XL-protein GmbH Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 T Cell Antigen Gp39 Industry Chain Analysis

7.2 T Cell Antigen Gp39 Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 T Cell Antigen Gp39 Production Mode & Process Analysis

7.4 T Cell Antigen Gp39 Sales and Marketing

7.4.1 T Cell Antigen Gp39 Sales Channels

7.4.2 T Cell Antigen Gp39 Distributors

7.5 T Cell Antigen Gp39 Customer Analysis

8 T Cell Antigen Gp39 Market Dynamics

8.1 T Cell Antigen Gp39 Industry Trends

8.2 T Cell Antigen Gp39 Market Drivers

8.3 T Cell Antigen Gp39 Market Challenges

8.4 T Cell Antigen Gp39 Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Biogen

Bristol Myers Squibb Company

eTheRNA Immunotherapies NV

ImmuNext

Juno Therapeutics Inc

MedImmune

Targovax AS

XL-protein GmbH

List of Tables

Table 1. Global T Cell Antigen Gp39 Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global T Cell Antigen Gp39 Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global T Cell Antigen Gp39 Market Competitive Situation by Manufacturers in 2024

Table 4. Global T Cell Antigen Gp39 Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global T Cell Antigen Gp39 Sales Market Share by Manufacturers (2020-2025)

Table 6. Global T Cell Antigen Gp39 Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global T Cell Antigen Gp39 Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market T Cell Antigen Gp39 Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of T Cell Antigen Gp39, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of T Cell Antigen Gp39, Product Type & Application

Table 12. Global Key Manufacturers of T Cell Antigen Gp39, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global T Cell Antigen Gp39 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in T Cell Antigen Gp39 as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global T Cell Antigen Gp39 Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global T Cell Antigen Gp39 Sales by Region (2020-2025) & (K Pcs)

Table 18. Global T Cell Antigen Gp39 Sales Market Share by Region (2020-2025)

Table 19. Global T Cell Antigen Gp39 Sales by Region (2026-2031) & (K Pcs)

Table 20. Global T Cell Antigen Gp39 Sales Market Share by Region (2026-2031)

Table 21. Global T Cell Antigen Gp39 Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global T Cell Antigen Gp39 Revenue Market Share by Region (2020-2025)

Table 23. Global T Cell Antigen Gp39 Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global T Cell Antigen Gp39 Revenue Market Share by Region (2026-2031)

Table 25. North America T Cell Antigen Gp39 Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America T Cell Antigen Gp39 Sales by Country (2020-2025) & (K Pcs)

Table 27. North America T Cell Antigen Gp39 Sales by Country (2026-2031) & (K Pcs)

Table 28. North America T Cell Antigen Gp39 Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America T Cell Antigen Gp39 Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe T Cell Antigen Gp39 Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe T Cell Antigen Gp39 Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe T Cell Antigen Gp39 Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe T Cell Antigen Gp39 Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe T Cell Antigen Gp39 Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific T Cell Antigen Gp39 Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific T Cell Antigen Gp39 Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific T Cell Antigen Gp39 Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific T Cell Antigen Gp39 Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific T Cell Antigen Gp39 Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America T Cell Antigen Gp39 Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America T Cell Antigen Gp39 Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America T Cell Antigen Gp39 Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America T Cell Antigen Gp39 Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America T Cell Antigen Gp39 Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa T Cell Antigen Gp39 Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa T Cell Antigen Gp39 Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa T Cell Antigen Gp39 Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global T Cell Antigen Gp39 Sales (K Pcs) by Type (2020-2025)

Table 51. Global T Cell Antigen Gp39 Sales (K Pcs) by Type (2026-2031)

Table 52. Global T Cell Antigen Gp39 Sales Market Share by Type (2020-2025)

Table 53. Global T Cell Antigen Gp39 Sales Market Share by Type (2026-2031)

Table 54. Global T Cell Antigen Gp39 Revenue (US$ Million) by Type (2020-2025)

Table 55. Global T Cell Antigen Gp39 Revenue (US$ Million) by Type (2026-2031)

Table 56. Global T Cell Antigen Gp39 Revenue Market Share by Type (2020-2025)

Table 57. Global T Cell Antigen Gp39 Revenue Market Share by Type (2026-2031)

Table 58. Global T Cell Antigen Gp39 Price (USD/Pcs) by Type (2020-2025)

Table 59. Global T Cell Antigen Gp39 Price (USD/Pcs) by Type (2026-2031)

Table 60. Global T Cell Antigen Gp39 Sales (K Pcs) by Application (2020-2025)

Table 61. Global T Cell Antigen Gp39 Sales (K Pcs) by Application (2026-2031)

Table 62. Global T Cell Antigen Gp39 Sales Market Share by Application (2020-2025)

Table 63. Global T Cell Antigen Gp39 Sales Market Share by Application (2026-2031)

Table 64. Global T Cell Antigen Gp39 Revenue (US$ Million) by Application (2020-2025)

Table 65. Global T Cell Antigen Gp39 Revenue (US$ Million) by Application (2026-2031)

Table 66. Global T Cell Antigen Gp39 Revenue Market Share by Application (2020-2025)

Table 67. Global T Cell Antigen Gp39 Revenue Market Share by Application (2026-2031)

Table 68. Global T Cell Antigen Gp39 Price (USD/Pcs) by Application (2020-2025)

Table 69. Global T Cell Antigen Gp39 Price (USD/Pcs) by Application (2026-2031)

Table 70. Biogen, Inc. Company Information

Table 71. Biogen, Inc. Description and Business Overview

Table 72. Biogen, Inc. T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Biogen, Inc. T Cell Antigen Gp39 Product

Table 74. Biogen, Inc. Recent Developments/Updates

Table 75. Bristol-Myers Squibb Company Company Information

Table 76. Bristol-Myers Squibb Company Description and Business Overview

Table 77. Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Bristol-Myers Squibb Company T Cell Antigen Gp39 Product

Table 79. Bristol-Myers Squibb Company Recent Developments/Updates

Table 80. eTheRNA Immunotherapies NV Company Information

Table 81. eTheRNA Immunotherapies NV Description and Business Overview

Table 82. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product

Table 84. eTheRNA Immunotherapies NV Recent Developments/Updates

Table 85. ImmuNext, Inc. Company Information

Table 86. ImmuNext, Inc. Description and Business Overview

Table 87. ImmuNext, Inc. T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. ImmuNext, Inc. T Cell Antigen Gp39 Product

Table 89. ImmuNext, Inc. Recent Developments/Updates

Table 90. Juno Therapeutics Inc. Company Information

Table 91. Juno Therapeutics Inc. Description and Business Overview

Table 92. Juno Therapeutics Inc. T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Juno Therapeutics Inc. T Cell Antigen Gp39 Product

Table 94. Juno Therapeutics Inc. Recent Developments/Updates

Table 95. MedImmune, LLC Company Information

Table 96. MedImmune, LLC Description and Business Overview

Table 97. MedImmune, LLC T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. MedImmune, LLC T Cell Antigen Gp39 Product

Table 99. MedImmune, LLC Recent Developments/Updates

Table 100. Targovax AS Company Information

Table 101. Targovax AS Description and Business Overview

Table 102. Targovax AS T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. Targovax AS T Cell Antigen Gp39 Product

Table 104. Targovax AS Recent Developments/Updates

Table 105. XL-protein GmbH Company Information

Table 106. XL-protein GmbH Description and Business Overview

Table 107. XL-protein GmbH T Cell Antigen Gp39 Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. XL-protein GmbH T Cell Antigen Gp39 Product

Table 109. XL-protein GmbH Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. T Cell Antigen Gp39 Distributors List

Table 113. T Cell Antigen Gp39 Customers List

Table 114. T Cell Antigen Gp39 Market Trends

Table 115. T Cell Antigen Gp39 Market Drivers

Table 116. T Cell Antigen Gp39 Market Challenges

Table 117. T Cell Antigen Gp39 Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of T Cell Antigen Gp39

Figure 2. Global T Cell Antigen Gp39 Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global T Cell Antigen Gp39 Market Share by Type: 2024 & 2031

Figure 4. ECI-006 Product Picture

Figure 5. Hepatitis B Vaccine Product Picture

Figure 6. INX-021 Product Picture

Figure 7. ISF-35 Product Picture

Figure 8. Others Product Picture

Figure 9. Global T Cell Antigen Gp39 Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global T Cell Antigen Gp39 Market Share by Application: 2024 & 2031

Figure 11. Graft Versus Host Disease

Figure 12. Breast Cancer

Figure 13. Bladder Cancer

Figure 14. Panceratic Cancer

Figure 15. Others

Figure 16. Global T Cell Antigen Gp39 Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global T Cell Antigen Gp39 Market Size (2020-2031) & (US$ Million)

Figure 18. Global T Cell Antigen Gp39 Sales (2020-2031) & (K Pcs)

Figure 19. Global T Cell Antigen Gp39 Average Price (USD/Pcs) & (2020-2031)

Figure 20. T Cell Antigen Gp39 Report Years Considered

Figure 21. T Cell Antigen Gp39 Sales Share by Manufacturers in 2024

Figure 22. Global T Cell Antigen Gp39 Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest T Cell Antigen Gp39 Players: Market Share by Revenue in T Cell Antigen Gp39 in 2024

Figure 24. T Cell Antigen Gp39 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global T Cell Antigen Gp39 Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America T Cell Antigen Gp39 Sales Market Share by Country (2020-2031)

Figure 27. North America T Cell Antigen Gp39 Revenue Market Share by Country (2020-2031)

Figure 28. U.S. T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe T Cell Antigen Gp39 Sales Market Share by Country (2020-2031)

Figure 31. Europe T Cell Antigen Gp39 Revenue Market Share by Country (2020-2031)

Figure 32. Germany T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific T Cell Antigen Gp39 Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific T Cell Antigen Gp39 Revenue Market Share by Region (2020-2031)

Figure 39. China T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Taiwan T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Indonesia T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Thailand T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Malaysia T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Philippines T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America T Cell Antigen Gp39 Sales Market Share by Country (2020-2031)

Figure 50. Latin America T Cell Antigen Gp39 Revenue Market Share by Country (2020-2031)

Figure 51. Mexico T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Middle East and Africa T Cell Antigen Gp39 Sales Market Share by Country (2020-2031)

Figure 55. Middle East and Africa T Cell Antigen Gp39 Revenue Market Share by Country (2020-2031)

Figure 56. Turkey T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. UAE T Cell Antigen Gp39 Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. Global Sales Market Share of T Cell Antigen Gp39 by Type (2020-2031)

Figure 60. Global Revenue Market Share of T Cell Antigen Gp39 by Type (2020-2031)

Figure 61. Global T Cell Antigen Gp39 Price (USD/Pcs) by Type (2020-2031)

Figure 62. Global Sales Market Share of T Cell Antigen Gp39 by Application (2020-2031)

Figure 63. Global Revenue Market Share of T Cell Antigen Gp39 by Application (2020-2031)

Figure 64. Global T Cell Antigen Gp39 Price (USD/Pcs) by Application (2020-2031)

Figure 65. T Cell Antigen Gp39 Value Chain

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-25N19924

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24B19783

Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20305

Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-12S20176

Mon Nov 24 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global T Cell Antigen Gp39 Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-11K10027

Global T Cell Antigen Gp39 Market Research Report 2025

FEATURED COMPANIES

T Cell Antigen Gp39 Market

Report Scope

Scope of T Cell Antigen Gp39 Market Report

Core Chapters

FAQ for this report

Who are the main players in the T Cell Antigen Gp39 Market report?

What are the Application segmentation covered in the T Cell Antigen Gp39 Market report?

What are the Type segmentation covered in the T Cell Antigen Gp39 Market report?

FEATURED COMPANIES

RELATED REPORTS